RT @ericdeinmd: Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE? 363 pt P2, double-blind PBO-controlled 48 w
Tweet Content
Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE
@RheumNow #ACRBest https://t.co/uamJe05odq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off